Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Pieris Pharmaceuticals, Inc. (PIRS : NSDQ)
 
 • Company Description   
Pieris Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's drug technology consists of Anticalin(R) to treat cancer, severe asthma, anemia and other medical conditions. Pieris Pharmaceuticals, Inc. is based in Freising-Weihenstephan, Germany.

Number of Employees: 141

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.69 Daily Weekly Monthly
20 Day Moving Average: 567,971 shares
Shares Outstanding: 74.10 (millions)
Market Capitalization: $125.23 (millions)
Beta: 1.19
52 Week High: $6.15
52 Week Low: $1.61
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -45.48% -40.26%
12 Week -47.19% -42.70%
Year To Date -55.29% -46.83%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
255 State Street 9th Floor
-
Boston,MA 02109
USA
ph: 857-246-8998
fax: 49-8161-141-1444
kelman@pieris.com http://www.pieris.com
 
 • General Corporate Information   
Officers
Stephen S. Yoder - President; Chief Executive Officer
James Geraghty - Chairman
Thomas Bures - Chief Financial Officer
Michael Richman - Director
Maya R. Said - Director

Peer Information
Pieris Pharmaceuticals, Inc. (CORR.)
Pieris Pharmaceuticals, Inc. (RSPI)
Pieris Pharmaceuticals, Inc. (CGXP)
Pieris Pharmaceuticals, Inc. (BGEN)
Pieris Pharmaceuticals, Inc. (GTBP)
Pieris Pharmaceuticals, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 720795103
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/03/22
Share - Related Items
Shares Outstanding: 74.10
Most Recent Split Date: (:1)
Beta: 1.19
Market Capitalization: $125.23 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.11 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.41 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/03/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.34
Price/Cash Flow: -
Price / Sales: 4.68
EPS Growth
vs. Year Ago Period: 0.00%
vs. Previous Quarter: 46.15%
Sales Growth
vs. Year Ago Period: -29.71%
vs. Previous Quarter: 30.14%
ROE
03/31/22 - -92.04
12/31/21 - -97.46
09/30/21 - -120.25
ROA
03/31/22 - -30.90
12/31/21 - -31.39
09/30/21 - -37.82
Current Ratio
03/31/22 - 2.83
12/31/21 - 2.52
09/30/21 - 2.77
Quick Ratio
03/31/22 - 2.83
12/31/21 - 2.52
09/30/21 - 2.77
Operating Margin
03/31/22 - -175.99
12/31/21 - -147.01
09/30/21 - -205.44
Net Margin
03/31/22 - -175.99
12/31/21 - -147.01
09/30/21 - -205.44
Pre-Tax Margin
03/31/22 - -174.31
12/31/21 - -145.58
09/30/21 - -202.97
Book Value
03/31/22 - 0.72
12/31/21 - 0.70
09/30/21 - 0.75
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©